Advertisement

Drugs & Therapy Perspectives

, Volume 35, Issue 1, pp 24–28 | Cite as

Be cautious when treating gout in patients with renal impairment

  • Adis Medical WritersEmail author
Disease Management
  • 25 Downloads

Abstract

Gout and renal impairment are frequent comorbidities, with both conditions strongly associated with hyperuricaemia. The management of gout involves treating and preventing gout flares, and reducing serum urate levels to eliminate the urate crystal deposits in the joints. Although the overall treatment of gout is very similar in patients with or without renal impairment, special precautions must be taken to avoid adverse effects related to renal impairment.

Notes

Compliance with ethical standards

Conflict of interest

The article was adapted from Drugs & Aging 2018;35(4):263–73 [4] by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.

Funding

The preparation of this review was not supported by any external funding.

References

  1. 1.
    Chen LX, Schumacher HR. Gout: an evidence-based review. J Clin Rheumatol. 2008;14(5 Suppl):S55–62.CrossRefGoogle Scholar
  2. 2.
    Newberry SJ, FitzGerald JD, Motala A, et al. Diagnosis of gout: a systematic review in support of an American College of Physicians Clinical Practice guideline. Ann Intern Med. 2017;166(1):27–36.CrossRefGoogle Scholar
  3. 3.
    Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.CrossRefGoogle Scholar
  4. 4.
    Pascual E, Sivera F, Andrés M. Managing gout in the patient with renal impairment. Drugs Aging. 2018;35(4):263–73.CrossRefGoogle Scholar
  5. 5.
    Yu KH, Kuo CF, Luo SF, et al. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Res Ther. 2012;14(2):R83.CrossRefGoogle Scholar
  6. 6.
    Perez-Ruiz F, Calabozo M, Herrero-Beites AM, et al. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron. 2000;86(3):287–91.CrossRefGoogle Scholar
  7. 7.
    Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68(1):51–6.CrossRefGoogle Scholar
  8. 8.
    Yang X, Yuan Y, Zhang CG, et al. Uricases as therapeutic agents to treat refractory gout: current states and future directions. Drug Dev Res. 2012;73(2):66–72.CrossRefGoogle Scholar
  9. 9.
    Chao J, Terkeltaub RA. Critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009;11:1135–40.CrossRefGoogle Scholar
  10. 10.
    Saito Y, Stamp LK, Caudle KE, Hershfield MS, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2015;99(1):36–7.CrossRefGoogle Scholar
  11. 11.
    White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200–10.CrossRefGoogle Scholar
  12. 12.
    Pui CH. Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother. 2002;3(4):433–42.CrossRefGoogle Scholar
  13. 13.
    Mejia-Chew C, Torres RJ, de Miguel E, et al. Resolution of massive tophaceous gout with three urate-lowering drugs. Am J Med. 2013;126(11):e9–10.CrossRefGoogle Scholar
  14. 14.
    Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig. 2014;34(12):845–55.CrossRefGoogle Scholar
  15. 15.
    Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15(1):123.CrossRefGoogle Scholar
  16. 16.
    Lyseng-Williamson KA. Canakinumab: a guide to its use in acute gouty arthritis flares. BioDrugs. 2013;27(4):401–6.CrossRefGoogle Scholar
  17. 17.
    Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264–71.CrossRefGoogle Scholar
  18. 18.
    Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447–61.CrossRefGoogle Scholar
  19. 19.
    Fernandez C, Noguera R, Gonzalez JA, et al. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol. 1999;26(10):2285–6.Google Scholar
  20. 20.
    Andrés M, Begazo A, Sivera F, et al. Intraarticular triamcinolone plus mepivacaine provides a rapid and sustained relief for acute gouty arthritis [abstract no. AB0815]. Ann Rheum Dis. 2016;75:1182.CrossRefGoogle Scholar
  21. 21.
    Terkeltaub RA. Clinical practice: gout. N Engl J Med. 2003;349(17):1647–55.CrossRefGoogle Scholar
  22. 22.
    Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72(6):826–30.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations